Explore blood exosomal miRNA as a biomarker for predicting the efficacy or risk of serious adverse reactions in patients with advanced lung adenocarcinoma (or lung squamous cell carcinoma) after anlotinib treatment.
Exosomes detection for the prediction of the efficacy and adverse reactions of Anlotinib in patients with advanced NSCLC